abrdn Healthcare Investors (HQH) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, abrdn Healthcare Investors (NYSE: HQH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $20.99 (-1.87% 1D, market cap $1.01B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1097 tracked Financials issuers, HQH ranks #553 in composite RQD confidence.
Within the Financials sector (Finance Companies), HQH carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BST (BlackRock Science and Technology Trust of) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.03B) and NCZ (Virtus Convertible & Income Fund II of) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.07B). Among the 5-stock peer group, JCAP leads on earnings multiple (6.1x) while JCAP leads on capital efficiency (55.2% ROIC).
For abrdn Healthcare Investors (HQH), key quantitative strengths include Established market leader in Financials with deep daily trading liquidity and sector rank #553 in Financials, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.7% FCF Margin ($28.4M FCF) & 52% Gross Margin
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
While HQH currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Financials with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.10) and Max Pain ($22.04) forces dealer call-delta covering toward $26.09.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
abrdn Healthcare Investors (HQH) slipped -1.87% to $20.99, trading at 50% of its 52-week range ($17.14 – $24.85). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Specialized CEFs provide institutional sector expertise without requiring deep personal industry knowledge. Read more on DFP and HQH CEFs here.
Weekly CEF update: sector performance, muni resilience, commodity weakness, HERZ tender results, and CLO equity selloff. Read the full analysis here.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HQH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HQH. Explore sector supply chains on /butterfly.
Across 1097 tracked Financials securities in the Roarable RQD universe, abrdn Healthcare Investors (HQH) ranks #553 by composite RQD confidence (54/100, grade D+) and #550 by equity capitalization ($1.01B). Within this direct 5-issuer industry benchmark cohort, JCAP leads on earnings valuation at 6.1x trailing P/E, while JCAP leads on capital efficiency and profitability with 55.2% ROIC and — gross margin. JCAP currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with HQH at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HQH
ACTIVE
abrdn Healthcare Investors | D+ | 54/100 | — | — | — | -1.87% | $1.01B | Benchmark Subject |
| BST BlackRock Science and Technology Trust of | D | 49/100 | — | — | — | -0.97% | $1.03B | /bst-vs-hqh → |
| NCZ Virtus Convertible & Income Fund II of | D | 44/100 | — | — | — | -0.07% | $1.07B | /ncz-vs-hqh → |
| JCAP Jefferson Capital Inc. | C+ | 69/100 | 6.1x | — | 55.2% | +2.84% | $1.13B | /jcap-vs-hqh → |
| NCV Virtus Convertible & Income Fund of | D- | 43/100 | — | — | — | -1.26% | $1.37B | /ncv-vs-hqh → |
abrdn Healthcare Investors (HQH) operates in Finance Companies (Financials) with an equity capitalization of $1.01B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, abrdn Healthcare Investors (NYSE: HQH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $20.99 (-1.87% 1D, market cap $1.01B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1097 tracked Financials issuers, HQH ranks #553 in composite RQD confidence.
Within the Financials sector (Finance Companies), HQH carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BST (BlackRock Science and Technology Trust of) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.03B) and NCZ (Virtus Convertible & Income Fund II of) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.07B). Among the 5-stock peer group, JCAP leads on earnings multiple (6.1x) while JCAP leads on capital efficiency (55.2% ROIC).
For abrdn Healthcare Investors (HQH), key quantitative strengths include Established market leader in Financials with deep daily trading liquidity and sector rank #553 in Financials, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
HQH last traded at $20.99 (-1.87% on volume of 165,896 shares), positioning the stock -0.52% below its 50-day simple moving average ($21.10) and +3.20% above its 200-day simple moving average ($20.34). Across its 52-week range of $17.14 to $24.85, HQH sits at the 49.9% percentile with a 14-day RSI of 61.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.8% ($19.77 to $22.21).
abrdn Healthcare Investors (HQH) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $20.99 (-1.87% 1D, market capitalization $1.01B).
abrdn Healthcare Investors (HQH) is a NYSE-listed operating company in the Finance Companies industry (Financials sector) with an equity market capitalization of $1.01B. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of 0% (free cash flow yield of 0%). Within the Finance Companies peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.
No upstream or downstream dependencies, sector correlations, or bottleneck links are mapped for HQH. A prospective investor should note that the absence of mapped links means this dossier cannot identify second-order ripples from the provided data.
Real-time company headlines, analyst actions, and sector developments for abrdn Healthcare Investors (HQH) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering abrdn Healthcare Investors (HQH) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating abrdn Healthcare Investors (HQH). The forensic balance sheet pillar scores 13 out of 20 with an Altman Z-Score of 2.5 and a Piotroski F-Score of 6/9, indicating relative balance-sheet stability.. With an RQD score of 54/100 (D+) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $23.10.
@MidwestValue Agree on the RQD 54/100 quality, though with 1.0 beta I'm scaling in with half-size at $21.39 and keeping dry powder in case we test $19.89.
Reported ROIC and FCF yield are both 0%, and insider conviction scores only 9 out of 20, leaving the rating without demonstrated cash returns or visible insider support.. Look at the math on HQH: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Finance Companies demand softens. I'd wait for a retest of $18.82 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: